

## Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference

August 6, 2019

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 39<sup>th</sup> Annual Growth Conference in Boston. The presentation is scheduled for Thursday, August 8, 2019 at 8:00 am ET.

The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at [www.intracellulartherapies.com](http://www.intracellulartherapies.com). Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

### About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone is under review by the FDA for the treatment of schizophrenia and is in Phase 3 clinical development for the treatment of bipolar depression. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease and for the treatment of heart failure.

### Contact:

Intra-Cellular Therapies, Inc.  
Juan Sanchez, M.D.  
Vice President, Corporate Communications and Investor Relations  
646-440-9333

Burns McClellan, Inc.  
Lisa Burns  
[jgrimaldi@burnsmc.com](mailto:jgrimaldi@burnsmc.com)  
212-213-0006



Source: Intra-Cellular Therapies Inc.